Abstract
Background
Adoptive cell therapy (ACT) for the treatment of cancer was pioneered in the 1980s using T cells harvested from the patients' own tumors [1] . Since then, autologous cellular immunotherapy approaches have expanded from using endogenous TILs to engineering cells to express selected T cell receptors [2] or to express chimeric antigen receptors that are not restricted by HLA type [3] . The CAR approach has been reproducibly successful in targeting CD19 in B cell acute lymphoblastic leukemia (ALL), leading to the first Federal Drug Administration (FDA) approval of Tisagenlecleucel in 2017. Shortly thereafter, the FDA approved Axicabtagene ciloleucel for the treatment of diffuse large B cell lymphoma.
ACT is derived from the observations that immune cells recognize and kill cancer cells [4] . Based on these observations it was posed that the anti-inflammatory environment of the tumor inhibited a de novo immune response. Clinical trials have tested numerous strategies for re-activating lymphocytes and other leukocyte subsets [5] . We chose a complementary approach, focusing on innate immunity [6] . The innate immune system, including monocytes, macrophages and NK cells, also plays a crucial function in controlling cancer [7] . Our initial studies re-examined the innate immune system as anti-cancer therapy. We showed that IFNα-2a or IFNγ-1b themselves are potently anti-neoplastic in vitro and in mouse models of ovarian cancer, and the effect was amplified with the addition of monocytes [8] .
Activated monocytes are capable of killing malignant cells [9] . Within tissues, monocytes can differentiate into inflammatory M1 macrophages with anti-cancer activity or suppressive M2 macrophages that promote tumor proliferation [10] [11] [12] . M2 macrophages are associated with poor prognosis in advanced epithelial ovarian cancer [13] . Therefore, the success of monocytes as an anti-tumor treatment approach depends on the ability to maintain M1 phenotype and avoid M2 differentiation in the tumor micro-environment. Importantly, our previous work showed both in vitro and in animal models, monocytes differentiated into M1 macrophages the presence of IFNα and IFNγ (increased IL-12, CXCL10, NOS2, and decreased IL-10, Arginase-1) [8] . We previously showed that monocytes stimulated with both IFNs are cytotoxic to six different ovarian cancer cell lines, and that this combination significantly improved tumor cell response to carboplatin and paclitaxel in vitro [14] . In mouse xenografts, intratumoral injection of monocytes with IFNs decreased ovarian cancer xenograft growth. With these promising results, we were encouraged to take this combination therapy forward to the clinical setting, while continuing to explore the molecular mechanism underlying the synergy between monocytes and interferons [15] . We designed a clinical trial to test the safety of four different dose combinations of monocytes and IFNs (Table 1) .
Methods for collecting monocytes have been optimized for the purpose of preparing dendritic cell vaccines [16] . In this procedure, the RO fraction contains the greatest number of monocytes. Despite the long historical use of counter flow elutriation, however, an analysis of critical immune cells in all 5 fractions has not been performed. Here, we define the sub-populations of immune cells in each fraction, show reproducibility of the product in producing large numbers of viable monocytes, and create a cryopreservation step to store multiple doses of the product from a single leukapheresis procedure. Patients underwent a 7-15 L PBMNC apheresis (autologous), as estimated by weight and target cell dose. Bilateral peripheral venous access was used whenever possible. Alternatively, a temporary central venous catheter (CVL) was placed for collection. Cells were processed for further manufacturing (Fig. 1) .
Cells manufactured in the current protocol are of autologous nature and donor eligibility determinations are not required (21 CFR 1271.90(a)(1)) [17] . However, eligibility requirements for product handling in our manufacturing facility require that subjects be HIV seronegative, hepatitis C seronegative and negative for Hepatitis B surface antigen. In addition, on the day of product collection, peripheral blood is submitted for testing: HIV 1 and 2 (antibody and NAT), HTLV I and II (antibody), Hepatitis C (antibody and NAT), Hepatitis B (surface antigen), West Nile Virus (NAT), T cruzi (antibody), and Treponema pallidum (antibody).
No feeder cells or cell lines were used in this protocol.
Fresh product
Apheresis products from four normal volunteer donors were collected sequentially in DTM within 2 weeks of one another. On the day of collection (day 0), the apheresis product was enriched for monocytes using counter-flow centrifugation (CCE) [18] . The enriched monocyte fraction was evaluated for total cell number and purity using the CellDyn automated cell counter. The product was then diluted with Plasmalyte A/4% HSA and 10 mcg/mL DNAse (Pulmozyme) for overnight storage. On the next day (day 1), the final product was prepared with Peginterferon alpha 2b (Sylatron 
Cryopreserved product
We designed and validated a new process that would allow us to prepare one initial fresh dose of monocytes and cryopreserve the remaining cells so that they may be thawed and infused at a later date. This new modification would reduce stress to the patient due to having to undergo multiple apheresis and relieves the burden of performing the procedure in a single apheresis clinic. Three separate samples were tested independently, two samples from healthy donors and one sample taken from a patient with ovarian cancer. Each sample was processed as a fresh and as a cryopreserved specimen.
Elutriated monocytes were cryopreserved with freeze mix containing 5% dimethyl sulfoxide (DMSO) as an intracellular cryoprotectant and 6% pentastarch as an extracellular cryoprotectant and 3.75% human serum albumin (HSA). Heparin and dornase alfa (DNAse) were added to minimize clumping at the time of thaw. Cells combined with freeze mix were cryopreserved in a controlled rate freezer (CRF) to a temperature of − 110 to − 120 °C and then stored in vapor phase of a liquid nitrogen (LN2) tank at − 150 to − 180 °C. Cells from donors were cryopreserved in aliquots 330 × 10 6 TNC (260 × 10 6 CD14/CD16 monocytes) and 990 × 10 6 TNC (780 × 10 6 CD14/CD16 monocytes).
Reagent information for creation of the final product
All product names, national drug code, and regulatory status can be found in Additional file 1: Table S14 .
Statistical analysis
Comparisons were made using two-way ANOVA with Tukey post hoc analysis to correct for multiple comparisons.
Results

Iterative isolation and production of fresh monocytes
Blood from healthy donors was used to validate the process. Seven to 8 L blood apheresis was collected from volunteer donors with TNC range of 6.17 × 10 9 -13.2 × 10 9 and total monocytes of 6.52 × 10 Table S1 ). Elutriation was performed on the same day of collection to enrich for monocytes and sample removed from each fraction post volume reduction to evaluate recovery and purity. Monocytes recovered from elutriated RO fraction from all four donors were sufficient to prepare final product at each dose level (Table 1) . We quantified immune subtypes by flow cytometric analysis of the four fractions of counter-flow elutriation, defining T cells (CD3), B cells (CD19), myeloid cells (HLA-DR), and NK cells/neutrophils (negative) (Fig. 3a) . Monocytes were further segregated from the myeloid population by CD14
Monocytes from healthy donor #1 were predominantly in the RO fraction, along with neutrophils and some of the dendritic cells (Fig. 3b, d ). In donor #2, monocytes were found in the RO fraction, and also in fraction 124, which also contained a large fraction of the dendritic cells (Fig. 3c, e) . Complete work-flow analysis is shown in Additional file 1: Table S2 , Additional file 2: Figure S1 , Additional file 3: Figure S2 , Additional file 4: Figure S3 and Additional file 5: Figure S4 .
Monocytes from RO fraction was transferred into a 600 mL Terumo bag and spun down to remove residual HBSS from elutriation procedure. Cells were then re-suspended in solution containing Plasmalyte-A/4% HSA/10 mcg/mL DNAse (Pulmozyme) at cell concentration of 5-10 × 10 6 /mL. A sample was removed for automated count, Trypan Blue viability and FACs prior to storage per SOP. Cell viability and monocyte purity before overnight storage from all four donors averaged ≥ 97% and 75.5% respectively (Fig. 2b and Additional file 1: Table S2 ).
The following day (day 1), stored cells were removed from refrigerator to warm to room temperature and filtered through a blood component recipient set to remove cell aggregates. A sample was removed for an automated cell count, TB viability and flow to evaluate for viability and cell loss. Average cell viability post storage from all donors remained > 95% with cell recovery > 92% (Fig. 2b , Additional file 1: Tables S4, S5 ).
The final product packaging on the first two donors was prepared at dose level 2 with 75 × 10 6 viable monocytes, 25 mcg SylatronTM and 5 mcg Actimmune (Fig. 4a, b) . All of these cells-classical, intermediate and non-classical-were included in the final product. Stability testing at room temperature (RT) for cell count and viability were performed 2 and 4 h post packaging. The viability at these time points remained > 90% for all four donors tested ( Table 1 ). The monocyte population was analyzed after 4 h incubation at room temperature in order to confirm the stability of the population in the maximum time frame expected to complete initial sterility testing and transfer the product to the patient for intraperitoneal infusion (Fig. 4c, d ).
Sterile cultures were submitted for bacterial/fungal sterility from the final product (FN). Results of Safety testing showed no growth (Additional file 1: Table S6 ). Mycoplasma PCR and Endotoxin testing was also negative.
Storage of monocytes using cryopreservation
First, we examined cell recovery following cryopreservation to ensure the cells were capable of surviving the cryopreservation process. Cells from all three donors were cryopreserved in aliquots > 330 × 10 6 TNC (or > 260 × 10 6 CD14/CD16 monocytes) (Additional file 1: Table S7 ). These aliquots represent the typical cell number that would be cryopreserved for use on an interventional clinical trial under development. Upon thaw, cells were counted and recovery was calculated. Total nucleated cell (TNC) recovery from all three samples was > 88% (> 91% for CD14/CD16 monocytes). We conclude that there is no detrimental effect of the cryopreservation procedure on the TNC or monocyte recovery.
Next, we compared the frequency of CD14/CD16 cells that were in the initial apheresis, in the fresh elutriated sample, and in the cryopreserved sample. After elutriation, we observed a consistent increase in the frequency of monocytes that were within the RO fraction. The frequency ranged from 14 to 43% in the starting bag to > 75% post elutriation (Additional file 1: Table S8 ). There (See figure on next page.) Fig. 2 Quantification of cell numbers and viability. Apheresis followed by counter-flow elutriation was performed on 4 healthy donors. a Total nucleated cells and total monocytes from the bullk apheresis shown for all donors as total cell number. b Total monocytes from the bulk apheresis. c Total Nucleated Cells in the RO fraction. d Total monocytes in the RO fraction. e Recovery of total nucleated cells from overnight storage was measured. f Viability of the final product monocytes at 0 h (black bars) and 4 h (grey bars) was measured. g Kinetics monocyte viability the on day 1 (black bars), day 2 (grey bars) and the final product were measured. h Total nucleated cell count was performed on the final product at 0 h (black bars), 2 h (grey bars), and 4 h (white bars) Table S9 ).
Monocyte viability pre and post cryopreservation was examined next. Samples were taken at day 1 and in the final product after resuspension with cytokines and assessed for viability using AO/PI uptake on the Cellometer instrument. The viability of all samples > 92% Table S3 , Additional file 2: Figure S1 , Additional file 3: Figure S2 , Additional file 4: Figure S3 and Additional file 5: Figure S4) ( Table 2 ). In addition, we examined the stability of the monocytes post thaw at 2 h and 4 h time points after final packaging with cytokines to ensure that they remained stable while they are transferred to the clinic for administration to the patient. We found that the viability at these time points was not significantly different than the viability at the 0 h time point (all > 93%) and conclude that the monocytes would remain stable for up to 4 h ( Table 3) .
Functional assays were performed using the final product from both the fresh and cryopreserved samples. Monocytes plus IFNs were mixed with ovarian cancer cells in vitro and allowed to incubate together for 3 days. Monocyte and IFN cytotoxicity was measured as absorbance with cell control having maxima cell viability. The freshly prepared product remained effective in killing OVCAR3 ovarian cancer cells after 5 h at room temperature (Fig. 5) . In addition, we tested cytotoxicity of the final product before and after cryopreservation. Three separate apheresis and elutriation runs were performed. At the time of product release, both final product (IFNs and monocytes) and the IFNs alone (supernatant) were assayed for toxicity using OVCAR3 cells as the target. Percent killing is calculated as (100% survival). There was no difference in cell killing effectiveness between the fresh and the frozen products or supernatants (Fig. 6 ). All samples were highly efficient in their ability to lyse target tumor cells.
The percent killing from all samples was > 94%, and the difference of percent killing between individual fresh vs. cryopreserved samples was < 2% (Additional file 1: Table S10 ). These data indicate that no loss of function occurred within the cryopreserved samples. A product release check list was created for the final product (Table 4 ).
In addition, we confirmed lack of toxicity to normal cells and tissues in vitro and in animals. Primary human hepatocytes, intestinal myofibroblasts, endothelial cells, and renal epithelial cells were purchased. Minimal decrease in viability occurred after 72 h exposure to IFNs alone and in combination with human monocytes in vitro, except in the endothelial cells at the highest concentrations of IFNs (Fig. 7) . Five groups of six nude mice each were treated with vehicle or four different dose combinations of human IFNs and human monocytes, to mimic a dose-escalating clinical trial (Table 5) . Necropsy was performed on all mice by a trained animal pathologist blinded to group allocation, and no definitive toxicity noted in any of the groups. One animal in the highest dose group had mild, multifocal, perivascular, lymphocytic infiltrate in the brain. Specific cause is unknown, but since this lesion was not seen in any other animal, the change was not thought to be treatment related. Mottled lungs were noted grossly at necropsy in several of the mice. This is a common incidental finding related to congestion/hemorrhage occurring at euthanasia. The lesion is often not present after tissues are processed. No biologically significant difference in the lungs was noted across the groups. Remaining lesions were sporadic, low , d) . The products were assayed for cytotoxicity to OVCAR3 ovarian cancer cells. Time 0 h product (black bars), product stored 4 h at room temperature (light grey), IFNs alone (dark grey), and cell medium supernatant without IFNs (white bar) were measured. e IFN stability was measured after incubation at room temperature for 0, 2, 4, and 5 h; initial (D1) and overnight (4c) monocyte supernatants are used as controls, for cytotoxicity with OVCAR3 cells in incidence and/or severity, and showed no relationship to dose or treatment.
Discussion
We have designed a processing scheme for the development of a clinical product comprised of autologous monocytes activated with IFNs alpha and gamma. Unlike other cell therapies which require complex processing, this therapy can be performed in any hospital with a transfusion center. The procedures are reproducible and scalable to account for the escalating doses on our phase 1 clinical trial. In order to minimize impact on the patient, we integrated a storage procedure that maintained potency of the final product. Having established the preclinical safety data and validated the monocyte processing methods, we filed an Investigational New Drug (IND) application and are proceeding with the phase 1 clinical trial in women with recurrent ovarian cancer (NCT02948426). The overall goal of this project is to optimize monocytes and IFNs as a therapeutic strategy for women with ovarian cancer, and to build on this backbone by introducing mechanistically synergistic agents in combination. While different combinations of IFNs and monocytes were tested in human clinical trials for their tumoricidal properties, the three have never been combined. Based on preclinical data showing increased efficacy of the triplet, we are taking a unique approach of stimulating innate immunity with intraperitoneal adoptive cell therapy, utilizing the strength of our institution's cell processing facility to develop this clinically.
Immune profiling of each elutriation fraction, as shown in Fig. 3 , demonstrates that there is donor ) , Sylatron, Actimmune, and monocytes (dark red bars) for 3 days and cell viability was measured using trypan blue. Staurosporine (black bars) was used as a positive control for cell toxicity. Experiments were performed three times with three healthy donor monocytes, except for the hepatocytes which were repeated three times with three separate primary hepatocyte donors. Yellow asterisks indicate comparison to cell control; purple indicate comparison to monocyte-only control. Numbers of asterisks indicate p-value as follows: * < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001 
